ISPOR Annual Conference 2019
Last month, Directors Brett Gardiner and Rachel Howard attended the ISPOR annual conference in New Orleans.
With over 4,000 delegates in attendance and a three-day program packed with panel presentations, poster sessions, educational symposia and workshops, this is the leading global conference for health economics and outcomes research.
EphMRA Annual Conference 2019
25-27 June 2019 Warsaw, Poland
We are delighted to be sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland 25-27 June. Representing Research Partnership are Director and EphMRA Board Member Richard Head, Director Paula Coyle, and Associate Director Emilie Braund. Also in attendance will be Associate Director An-hwa Lee who sits on the EphMRA Learning and Development Committee, which plans to convene before the conference begins.
Intellus Worldwide Summit round up 2019
This May, Liza Pliss, Director and Head of our New York Office, Sabera Hyderally, Director, Head of MedTech Division North America and Emily Hoffman, Associate Director exhibited at and attended the Intellus Worldwide Summit in Philadelphia.
Intellus Worldwide Summit 2019
Visit us at stand 311
We are delighted to be exhibiting at the Intellus Worldwide Summit in Philadelphia, USA from 19th-21st May. Representing Research Partnership at the event will be Liza Pliss, Director and Head of our New York Office, Sabera Hyderally, Director, Head of MedTech Division North America and Emily Hoffman, Associate Director.
World Pharma Pricing and Market Access Congress 2019
Last month, Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam.
This two-day event was attended by over 600 delegates, including a number of payers from Europe, the US and Latin America, plus representatives from the industry and other market access organizations. In the morning plenary sessions, we heard a range of perspectives on value, demonstrating that “value is in the eye of the beholder”. A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy.